DelveInsight’s Chemotherapy Induced Neutropenia Market Research, Epidemiology, and Market Forecast–2030’ report delivers an in-depth understanding of the CIN, historical and forecasted epidemiology as well as the CIN market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The Chemotherapy-Induced Neutropenia market research report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM CIN market size from 2018 to 2030. The Report also covers current CIN treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Chemotherapy-Induced Neutropenia (CIN) is the primary dose-limiting toxicity in patients with cancer treated with chemotherapy. It can lead to febrile neutropenia (FN), and it is associated with increased morbidity and early mortality, increased medical costs, and disruptions in potentially curative treatments. The symptoms of CIN that most patients observe are chills or sweating, Sore throat, sores in the mouth, or a toothache, abdominal pain, pain near the anus, and others.
The initial evaluation of a patient with CIN includes medical history, initial physical assessments, urinalysis, sputum, stool cultures, laboratory tests—including complete blood cell counts with differential leukocyte and platelet counts—are needed to determine ANC and neutropenia severity.
About Chemotherapy Induced Neutropenia Market Companies
The management of CIN involves two main strategies: modification of the chemotherapy regimen and/or the use of growth factors. The optimal strategy for the management of CIN is prevention. In the management of CIN, myeloid growth factors (MGFs), including G-CSF and granulocyte macrophage-colony stimulating factor (GM-CSF), are used in clinical practice to reduce the risk of febrile neutropenia (FN) and its complications. Currently, there are four recombinant G-CSF formulations: filgrastim (nonglycosylated), lenograstim (glycosylated), pegfilgrastim (filgrastim in pegylated version), and lipefilgrastim (filgrastim in glycosylate version). Biosimilar versions exist for filgrastim and pegfilgrastim. The pegylated version differs for the different plasma half-life, much longer than the non-pegylated version (3–4 h), and allows a single administration of the drug per chemotherapy cycle.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by the Total number of patients on chemotherapy, Risk-specific chemotherapy patient pool for CIN, and Total incident cases of CIN by cancer type scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.
Original Source:- Chemotherapy Induced Neutropenia Market Drugs
